A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MS / multisystem

[Related PubMed/MEDLINE]
Total Number of Papers: 25
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MS  (>> Co-occurring Abbreviation)
Long Form:   multisystem
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis. HLH, LCH
2019 Langerhans Cell Histiocytosis: Single Center Experience of 25 Years. EFS, OS, SS
2019 Remission of Congenital Multi-system Type Langerhans Cell Histiocytosis with Chemotherapy. LCH
2018 Clinical course of the bony lesion of single-system single-site Langerhans cell histiocytosis - Is appropriate follow-up sufficient treatment? CRP, LCH, PET, SS-m, SS-s
2018 Fever and Skin Involvement at Diagnosis Predicting the Intractable Langerhans Cell Histiocytosis: 40 Case-Series in a Single Center. LCH, ROs
2018 Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India. LCH, SS
2016 Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: A single-center retrospective study. CEVP, LCH, SS-m, VP
2016 Pediatric langerhans cell histiocytosis: single center experience over a 17-year period. LCH, SS
2015 High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience. LCH, SS-m
10  2015 Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood. LCH
11  2014 Clinical features and treatment outcomes of Langerhans cell histiocytosis: a nationwide survey from Korea histiocytosis working party. LCH, MS-RO, OS, SS
12  2013 Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group. LCH, NAD, SS
13  2010 Langerhans cell histiocytosis: Current concepts and treatments. LCH
14  2010 MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. CR, LCH, MACOP-B, PET, PR, SS-m
15  2010 Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan. 2-CdA, LCH, MFB, RO
16  2009 An infant with self-healing cutaneous Langerhans cell histiocytosis followed by isolated thymic relapse. LCH
17  2008 Incidence of Langerhans cell histiocytosis in children: a population-based study. SS
18  2008 Skeletal Langerhans cell histiocytosis in children: permanent consequences and health-related quality of life in long-term survivors. LCH, PC, QOL, SS
19  2007 Response to subcutaneous therapy with mistletoe in recurrent multisystem Langerhans cell histiocytosis. LCH, MT
20  2006 Cutaneous Langerhans cell histiocytosis in children under one year. LCH
21  2006 Elevated serum levels of the decoy receptor osteoprotegerin in children with Langerhans cell histiocytosis. LCH, OPG, SS, TNF
22  2006 Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. JLSG-96, LCH, PSL, SS-m, VCR
23  2006 Pulmonary Langerhans cell histiocytosis: a variable disease in childhood. PLCH, SS
24  2005 Langerhans cell histiocytosis in neonates. LCH, ROs, SS
25  2004 Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. DI, HS, LCH, PC, SS